- Home
- CBLL vs COLL Comparison
CBLL vs COLL Comparison
Compare CBLL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBLL
- COLL
- Stock Information
- Founded
- CBLL 2014
- COLL 2002
- Country
- CBLL United States
- COLL United States
- Employees
- CBLL N/A
- COLL N/A
- Industry
- CBLL
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CBLL
- COLL Health Care
- Exchange
- CBLL Nasdaq
- COLL Nasdaq
- Market Cap
- CBLL 767.6M
- COLL 910.2M
- IPO Year
- CBLL 2024
- COLL 2015
- Fundamental
- Price
- CBLL $19.46
- COLL $29.71
- Analyst Decision
- CBLL Strong Buy
- COLL Strong Buy
- Analyst Count
- CBLL 5
- COLL 5
- Target Price
- CBLL $33.25
- COLL $43.60
- AVG Volume (30 Days)
- CBLL 177.6K
- COLL 466.9K
- Earning Date
- CBLL 05-14-2025
- COLL 05-08-2025
- Dividend Yield
- CBLL N/A
- COLL N/A
- EPS Growth
- CBLL N/A
- COLL 43.56
- EPS
- CBLL N/A
- COLL 1.86
- Revenue
- CBLL $65,444,000.00
- COLL $631,449,000.00
- Revenue This Year
- CBLL $30.47
- COLL $19.43
- Revenue Next Year
- CBLL $29.61
- COLL $3.34
- P/E Ratio
- CBLL N/A
- COLL $16.00
- Revenue Growth
- CBLL 44.71
- COLL 11.41
- 52 Week Low
- CBLL $18.69
- COLL $27.28
- 52 Week High
- CBLL $32.75
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- CBLL N/A
- COLL 48.90
- Support Level
- CBLL N/A
- COLL $29.33
- Resistance Level
- CBLL N/A
- COLL $30.84
- Average True Range (ATR)
- CBLL 0.00
- COLL 0.85
- MACD
- CBLL 0.00
- COLL 0.08
- Stochastic Oscillator
- CBLL 0.00
- COLL 50.11
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.